Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics - PubMed
Review
doi: 10.1038/clpt.2013.148. Epub 2013 Jul 18.
Affiliations
- PMID: 23867542
- DOI: 10.1038/clpt.2013.148
Review
Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics
I Grattagliano et al. Clin Pharmacol Ther. 2014 Jan.
Erratum in
- Clin Pharmacol Ther. 2014 Jan;95(1):110
Abstract
Familial Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis, arthritis, serositis, and skin and oral lesions. Diagnosis is based on clinical features, response to treatment with colchicine, and genetic analysis. Colchicine prevents attacks and renal amyloidosis, in addition to reversing proteinuria. Nonresponders may receive novel therapy, including interleukin (IL)-1 receptor antagonists and IL-1 decoy receptor. Recently, new options have been considered.
Similar articles
-
Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
Portincasa P, Scaccianoce G, Palasciano G. Portincasa P, et al. Eur J Clin Invest. 2013 Dec;43(12):1314-27. doi: 10.1111/eci.12170. Epub 2013 Oct 14. Eur J Clin Invest. 2013. PMID: 24117178 Review.
-
Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, Lachmann HJ, Lang U, Kovarik J. Moser C, et al. Nephrol Dial Transplant. 2009 Feb;24(2):676-8. doi: 10.1093/ndt/gfn646. Epub 2008 Nov 25. Nephrol Dial Transplant. 2009. PMID: 19033248
-
Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.
Sozeri B, Kasapcopur O. Sozeri B, et al. Curr Med Chem. 2015;22(16):1986-91. doi: 10.2174/0929867322666150311152300. Curr Med Chem. 2015. PMID: 25760087 Review.
-
Familial Mediterranean fever, review of the literature.
Alghamdi M. Alghamdi M. Clin Rheumatol. 2017 Aug;36(8):1707-1713. doi: 10.1007/s10067-017-3715-5. Epub 2017 Jun 18. Clin Rheumatol. 2017. PMID: 28624931 Review.
-
[Familial Mediterranean Fever (FMF): from diagnosis to treatment].
Medlej-Hashim M, Loiselet J, Lefranc G, Mégarbané A. Medlej-Hashim M, et al. Sante. 2004 Oct-Dec;14(4):261-6. Sante. 2004. PMID: 15745878 Review. French.
Cited by
-
Periodontal and other oral manifestations of immunodeficiency diseases.
Peacock ME, Arce RM, Cutler CW. Peacock ME, et al. Oral Dis. 2017 Oct;23(7):866-888. doi: 10.1111/odi.12584. Epub 2016 Oct 10. Oral Dis. 2017. PMID: 27630012 Free PMC article. Review.
-
Decreased Chitotriosidase Activity and Levels in Familial Mediterranean Fever.
Doğan HO, Omma A, Turhan T, Boğdaycıoğlu N, Karaaslan Y, Yavuz H, Demirpençe Ö, Aydın H, Bakır S. Doğan HO, et al. J Korean Med Sci. 2016 Dec;31(12):1902-1906. doi: 10.3346/jkms.2016.31.12.1902. J Korean Med Sci. 2016. PMID: 27822927 Free PMC article.
-
Gemilyan M, Hakobyan G, Ananyan S. Gemilyan M, et al. J Med Case Rep. 2018 May 18;12(1):130. doi: 10.1186/s13256-018-1691-2. J Med Case Rep. 2018. PMID: 29773081 Free PMC article.
-
Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F. Özçakar ZB, et al. Clin Rheumatol. 2016 Feb;35(2):441-6. doi: 10.1007/s10067-014-2772-2. Epub 2014 Sep 13. Clin Rheumatol. 2016. PMID: 25213327
-
Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.
Demirkaya E, Erer B, Ozen S, Ben-Chetrit E. Demirkaya E, et al. Rheumatol Int. 2016 Mar;36(3):325-31. doi: 10.1007/s00296-015-3408-9. Epub 2015 Dec 19. Rheumatol Int. 2016. PMID: 26687683 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources